全文获取类型
收费全文 | 30470篇 |
免费 | 2785篇 |
国内免费 | 973篇 |
专业分类
耳鼻咽喉 | 438篇 |
儿科学 | 707篇 |
妇产科学 | 278篇 |
基础医学 | 2538篇 |
口腔科学 | 1483篇 |
临床医学 | 2452篇 |
内科学 | 4511篇 |
皮肤病学 | 388篇 |
神经病学 | 994篇 |
特种医学 | 1759篇 |
外国民族医学 | 4篇 |
外科学 | 7664篇 |
综合类 | 4029篇 |
现状与发展 | 4篇 |
一般理论 | 1篇 |
预防医学 | 1972篇 |
眼科学 | 530篇 |
药学 | 2225篇 |
14篇 | |
中国医学 | 1057篇 |
肿瘤学 | 1180篇 |
出版年
2024年 | 60篇 |
2023年 | 515篇 |
2022年 | 772篇 |
2021年 | 1202篇 |
2020年 | 1125篇 |
2019年 | 1191篇 |
2018年 | 1332篇 |
2017年 | 1147篇 |
2016年 | 1138篇 |
2015年 | 1092篇 |
2014年 | 2015篇 |
2013年 | 2225篇 |
2012年 | 1561篇 |
2011年 | 1718篇 |
2010年 | 1260篇 |
2009年 | 1294篇 |
2008年 | 1478篇 |
2007年 | 1388篇 |
2006年 | 1333篇 |
2005年 | 1158篇 |
2004年 | 1023篇 |
2003年 | 990篇 |
2002年 | 845篇 |
2001年 | 737篇 |
2000年 | 612篇 |
1999年 | 560篇 |
1998年 | 577篇 |
1997年 | 488篇 |
1996年 | 414篇 |
1995年 | 382篇 |
1994年 | 349篇 |
1993年 | 276篇 |
1992年 | 257篇 |
1991年 | 240篇 |
1990年 | 180篇 |
1989年 | 168篇 |
1988年 | 116篇 |
1987年 | 107篇 |
1986年 | 96篇 |
1985年 | 108篇 |
1984年 | 111篇 |
1983年 | 68篇 |
1982年 | 75篇 |
1981年 | 64篇 |
1980年 | 57篇 |
1979年 | 47篇 |
1978年 | 53篇 |
1977年 | 38篇 |
1976年 | 41篇 |
1975年 | 30篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
11.
12.
《Vaccine》2019,37(47):6987-6995
Vero cells are nowadays widely used in the production of human vaccines. They are considered as one of the most productive and flexible continuous cell lines available for vaccine manufacturing. However, these cells are anchorage dependent, which greatly complicates upstream processing and process scale-up. Moreover, there is a recognized need to reduce the costs of vaccine manufacturing to develop vaccines that are affordable worldwide. The use of cell lines adapted to suspension growth contributes to reach this objective.The current work describes the adaptation of Vero cells to suspension culture in different serum free media according to multiple protocols based on subsequent passages. The best one that relies on cell adaption to IPT-AFM an in-house developed animal component free medium was then chosen for further studies. Besides, as aggregates have been observed, the improvement of IPT-AFM composition and mechanical dissociation were also investigated.In addition to IPT-AFM, three chemically defined media (CD293, Hycell CHO and CD-U5) and two serum free media (293SFMII and SFM4CHO) were tested to set up a serum free culture of the suspension-adapted Vero cells (VeroS) in shake flasks. Cell density levels higher than 2 × 106 cells/mL were obtained in the assessed conditions. The results were comparable to those obtained in spinner culture of adherent Vero cells grown on Cytodex 1 microcarriers.Cell infection with LP-2061 rabies virus strain at an MOI (Multiplicity of Infection) of 0.1 and a cell density of 8 ± 0.5 × 105 cells/mL resulted in a virus titer higher than 107 FFU/mL in all media tested. Nevertheless, the highest titer equal to 5.2 ± 0.5 × 107 FFU/mL, was achieved in IPT-AFM containing a reduced amount of Ca++ and Mg++. Our results demonstrate the suitability of the obtained VeroS cells to produce rabies virus at a high titer, and pave the way to develop VeroS cells bioreactor process for rabies vaccine production. 相似文献
13.
14.
15.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献
16.
17.
《Journal of vascular and interventional radiology : JVIR》2020,31(4):630-634
PurposeTo retrospectively evaluate the safety and effectiveness of the Covera stent graft (SG) for the treatment of dysfunctional or thrombosed arteriovenous grafts (AVGs).Materials and MethodsWithin 29 months (February 2016–August 2018), 79 patients underwent Covera SG placement in the authors’ department for the treatment of dysfunctional AVGs. Data were available for 64 patients who underwent 64 procedures, using 64 devices. Minimum follow-up was 6 months, unless reintervention occurred. Mean follow-up was 277 days (6–923 days). Treatment characteristics were 51 cases with venous-graft anastomosis (VGA) stenosis (79.7%), 13 cases of puncture zone stenosis (20.3%), 14 cases of in SG stenosis (21.9%), 8 cases of pseudoaneurysm treatment (12.5%) (1 treatment area might have had more than 1 characteristic). Thirty-six patients presented with thrombosis (56.2%), and 31 of 64 case were de novo treatment areas (48.4%). Primary outcome measurements were technical success and post-intervention primary patency (PIPP) at 6 months, whereas secondary outcome measurements included factors influencing primary outcome.ResultsTechnical success was 100%. Median PIPP was 336 days, and 73.6% of treatment areas were patent at 6 months. There were no significant differences in terms of PIPP when de novo treatment areas were compared with restenotic areas (519 vs. 320 days, respectively; P = .1); patients who presented with versus those who presented without thrombosis (320 vs. 583 days, respectively; P = .07); puncture zone stenosis or elsewhere (329 vs. 686 days, respectively; P = .52); and VGA stenosis or elsewhere (336 vs. 335 days, respectively; P = .9).ConclusionsUse of the Covera SG for AVG treatment was safe and effective in every type of treatment area presented in this retrospective analysis. 相似文献
18.
Changes in Right Ventricular Shape and Deformation Following Coronary Artery Bypass Surgery—Insights from Echocardiography with Strain Rate and Magnetic Resonance Imaging 下载免费PDF全文
19.
20.
目的通过建立去势比格犬模型,观察绝经早期腹部脂肪变化规律,并通过对脂肪与骨代谢相关血清学指标的测量与分析,探讨脂肪及骨代谢的关键影响因素。方法选取6只成年雌性比格犬进行去势术,分别在术前、术后4个月、6个月、10个月进行腰椎定量CT(quantatitive computed tomography,QCT)腹部脂肪面积、骨密度(bone mineral density,BMD)、MRI腰椎骨髓脂肪含量及血清学指标的检测,比较不同时间各指标的变化趋势及关系。结果比格犬腹内脂肪面积(visceral fat area,VFA)、皮下脂肪面积(subcutaneous fat area,SFA)、腹部总脂肪面积(total fat area,TFA)在术后6个月、10个月均增加(P0.05),术后10个月VFA增加百分比均值为84.39%,且为三者中最大;术后比格犬BMD并未明显降低。体重、BMD、瘦素(leptin,LP)、VFA、高密度脂蛋白(high-density lipoprotein,HDL)与SFA相关。SFA、体重、低密度脂蛋白(low-density lipoprotein,LDL)、内脏脂肪素(visfatin,VFN)与BMD相关。结论去势比格犬模型可用于研究绝经后雌激素缺乏所引起的脂肪代谢变化,但短期内BMD并未明显丢失,骨、脂肪代谢之间存在交互作用。 相似文献